Luca Issi
Stock Analyst at RBC Capital
(1.06)
# 3,518
Out of 4,712 analysts
168
Total ratings
27.45%
Success rate
-16.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Sector Perform | $5 → $4 | $1.21 | +230.58% | 8 | Dec 13, 2024 | |
| QURE uniQure | Maintains: Outperform | $14 → $20 | $17.35 | +15.27% | 5 | Dec 11, 2024 | |
| RGNX REGENXBIO | Reiterates: Outperform | $35 | $7.40 | +372.97% | 8 | Dec 11, 2024 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $45 | $23.97 | +87.73% | 1 | Nov 26, 2024 | |
| RNA Avidity Biosciences | Initiates: Outperform | $67 | $31.35 | +113.72% | 1 | Nov 26, 2024 | |
| BLUE bluebird bio | Reiterates: Sector Perform | $80 | $7.79 | +926.96% | 5 | Nov 15, 2024 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $9 → $11 | $6.17 | +78.28% | 5 | Nov 14, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $40 → $39 | $5.81 | +571.26% | 6 | Nov 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Outperform | $77 | $43.75 | +76.00% | 3 | Nov 6, 2024 | |
| VERV Verve Therapeutics | Maintains: Outperform | $20 → $17 | $5.77 | +194.63% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $53 | $40.94 | +29.46% | 12 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $24 | $33.32 | -27.97% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $27 → $24 | $28.81 | -16.70% | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $10 | $4.74 | +110.97% | 6 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $243.25 | +23.33% | 23 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $66.63 | +20.07% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $13.41 | +11.86% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $105 | $43.30 | +142.49% | 6 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $36.53 | +91.62% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $19.63 | +113.96% | 7 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $75 | $40.27 | +86.24% | 12 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $12.05 | +348.13% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $6.35 | +277.95% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.69 | +728.40% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.09 | +378.47% | 7 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $2.50 | -20.00% | 5 | Mar 14, 2024 |
Editas Medicine
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.21
Upside: +230.58%
uniQure
Dec 11, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $17.35
Upside: +15.27%
REGENXBIO
Dec 11, 2024
Reiterates: Outperform
Price Target: $35
Current: $7.40
Upside: +372.97%
Dyne Therapeutics
Nov 26, 2024
Initiates: Outperform
Price Target: $45
Current: $23.97
Upside: +87.73%
Avidity Biosciences
Nov 26, 2024
Initiates: Outperform
Price Target: $67
Current: $31.35
Upside: +113.72%
bluebird bio
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $7.79
Upside: +926.96%
MeiraGTx Holdings
Nov 14, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $6.17
Upside: +78.28%
4D Molecular Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $40 → $39
Current: $5.81
Upside: +571.26%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $43.75
Upside: +76.00%
Verve Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $20 → $17
Current: $5.77
Upside: +194.63%
Nov 6, 2024
Reiterates: Sector Perform
Price Target: $53
Current: $40.94
Upside: +29.46%
Nov 6, 2024
Maintains: Sector Perform
Price Target: $25 → $24
Current: $33.32
Upside: -27.97%
Nov 6, 2024
Maintains: Sector Perform
Price Target: $27 → $24
Current: $28.81
Upside: -16.70%
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $4.74
Upside: +110.97%
Nov 1, 2024
Reiterates: Outperform
Price Target: $300
Current: $243.25
Upside: +23.33%
Oct 30, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $66.63
Upside: +20.07%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $13.41
Upside: +11.86%
Oct 21, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $43.30
Upside: +142.49%
Sep 26, 2024
Reiterates: Outperform
Price Target: $70
Current: $36.53
Upside: +91.62%
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $19.63
Upside: +113.96%
Sep 19, 2024
Reiterates: Sector Perform
Price Target: $75
Current: $40.27
Upside: +86.24%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $12.05
Upside: +348.13%
Aug 13, 2024
Reiterates: Outperform
Price Target: $24
Current: $6.35
Upside: +277.95%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.69
Upside: +728.40%
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.09
Upside: +378.47%
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $2.50
Upside: -20.00%